The modelled cost-effectiveness analysis of dacomitinib as a first-line treatment for patients with locally advanced or metastatic EGFR-mutation-positive NSCLC in China was associated with an ICER of CNY 58,947/QALY compared with gefitinib over a 15-year time period. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.